Archives
-
Tubastatin A for Reliable Cell Assays
2026-10-01
Learn how Tubastatin A (SKU A4101) can improve the interpretation and reproducibility of cell viability, proliferation, and cytotoxicity workflows through selective HDAC6 inhibition. This scenario-based guide connects practical assay design with biochemical potency, solvent handling, and emerging translational evidence.
-
6-OHDA Hydrochloride: Mechanism and Workflow
2026-09-30
6-OHDA hydrochloride is a catecholaminergic neurotoxin used to create experimental neuronal lesion models. Its transporter-dependent uptake and oxidative injury mechanism is distinct from the 25-hydroxycholesterol pathway described in tumor-associated macrophages.
-
Itraconazole: Mechanism and Candida Biofilm Research
2026-09-30
Itraconazole is a triazole antifungal agent with reported activity against Candida species and documented CYP3A4 interaction utility. Its product-reported benchmarks support solvent planning, while recent Candida albicans biofilm research shows that PP2A-driven autophagy can alter antifungal resistance without directly validating itraconazole treatment.
-
Dyngo-4a: Mapping Dynamin-Dependent LNP Uptake
2026-09-29
Dyngo-4a provides a practical perturbation tool for testing whether dynamin-dependent membrane trafficking contributes to lipid nanoparticle delivery, rather than merely measuring final mRNA expression. This workflow extends serial human T-cell engineering studies with matched uptake, expression, and viability readouts while clearly separating established evidence from proposed mechanistic experiments.
-
HyperScribe Co-transcription mRNA Synthesis Kit Plus
2026-09-29
Build translation-ready, ARCA-capped transcripts with a template-encoded poly(A) tail for in vitro translation, RNA vaccine development, and RNA interference studies. This workflow-focused guide connects reliable mRNA synthesis with practical assay design, quality control, and nanovaccine research limitations.
-
Necrostatin-1: From RIP1 Biology to Translation
2026-09-28
A translational framework for using Necrostatin-1 as a RIP1 kinase inhibitor to connect necroptosis, inflammatory signaling, and tissue-injury models.
-
From RNA Nanocarriers to Translational Readouts
2026-09-28
A new potato virus X-based platform illustrates how programmable protein–RNA assemblies could expand nucleic acid delivery research. Translational teams can pair this kind of platform innovation with carefully designed qPCR workflows—while recognizing that nucleic acid detection is not, by itself, evidence of functional delivery.
-
AZD0156 and the Metabolic Logic of ATM Inhibition
2026-09-27
Explore how AZD0156, an ATM kinase inhibitor, can help investigate the intersection of DNA repair and tumor metabolism. Using high-grade serous ovarian cancer findings, this article explains how to distinguish a true combination effect from a simple loss of viability.
-
DiscoveryProbe™ Immunology/Inflammation Library
2026-09-26
Explore how the DiscoveryProbe Immunology/Inflammation Compound Library can support rigorous immunomodulator screening. This article focuses on turning multiplex immune-cell phenotypes into stronger, better-controlled inflammation target validation.
-
Patient-Derived Gastric Cancer Assembloids
2026-09-25
This study introduces patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell populations, bringing key features of the tumor microenvironment into an in vitro model. The authors show that stromal inclusion can reshape gene expression and drug sensitivity, supporting more context-aware preclinical testing while leaving clinical predictive value to be established.
-
Doxorubicin Workflows for Cancer and Cardiac Screens
2026-09-25
Use Doxorubicin as a mechanism-informed reference for cancer-cell response assays and as a carefully interpreted perturbagen in iPSC-cardiomyocyte toxicity screens. This workflow connects dose and exposure design with high-content imaging, deep-learning phenotyping, and practical troubleshooting—without treating a cardiac signal as a measure of anticancer efficacy.
-
Mosquito Xenobiotic Transport After Alizarin Exposure
2026-09-24
Kennel and Rouhier tested how three injected xenobiotics affect excretion and putative organic cation transporter expression in female Aedes aegypti. Their results point to a stronger effect of chemical structure on excreted material and mortality than on the measured transporter transcripts, while highlighting how much remains unknown about mosquito xenobiotic transport.
-
25-Hydroxycholesterol Reprograms Tumor Macrophages
2026-09-24
Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic signal that accumulates in tumor-associated macrophage lysosomes and promotes an AMPKα–STAT6–ARG1 program. The study connects cholesterol sensing to macrophage-mediated immune suppression and reports that targeting CH25H can improve antitumor responses, including with anti-PD-1 therapy.
-
FAISL Stabilizes FAK to Drive TNBC Metastasis
2026-09-23
The study identifies FAISL, a long noncoding RNA, as a protein-level regulator of focal adhesion kinase (FAK): by binding FAK and limiting calpain 2 access, FAISL protects FAK from proteolysis and supports triple-negative breast cancer progression. Patient-tissue associations, cell experiments, and nanoparticle-mediated FAISL silencing in mouse models connect this mechanism to tumor growth and metastasis, while leaving its clinical applicability to be established.
-
Lysosomal β-Galactosidase Staining Kit Workflow
2026-09-23
Use the Lysosomal β-Galactosidase Staining Kit to visualize acidic lysosomal activity as a brightfield control readout in cell and tissue workflows. Its polystyrene compatibility and precipitation-resistant formulation help separate genuine biology from handling artifacts, especially in senescence and cisplatin-resistance studies.